TARSUS PHARMACEUTICALS INC (TARS) Stock News
NASDAQ:TARS - Nasdaq - US87650L1035 - Common Stock - Currency: USD
TARS Latest News, Press Relases and Analysis
Tarsus to Participate in Upcoming Investor Conferences
IRVINE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the...
Tarsus to Participate in Upcoming Investor Conferences
Tarsus Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Tarsus Pharmaceuticals (TARS) Loses -15.59% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Tarsus Pharmaceuticals (TARS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
HCA Healthcare to Report Q1 Earnings: Key Estimates to Note
HCA's first-quarter earnings are likely to have benefited from growing admissions.
United Airlines Holdings, Inc. (UAL): Among Billionaire Ken Griffin’s Midcap Stock Picks with Huge Upside Potential
We recently published a list of Billionaire Ken Griffin’s 10 Midcap Stock Picks with Huge Upside Potential. In this article, we are going to take a look at where United Airlines Holdings, Inc. (NASDAQ:UAL) stands against Billionaire Ken Griffin’s other midcap stock picks with huge upside potential. Ken Griffin, the founder of Citadel, is an influential […]
Tarsus to Participate in Upcoming Investor Conferences
IRVINE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that management plans to participate in the...
Tarsus to Participate in Upcoming Investor Conferences
Zai Lab Limited (ZLAB): Among the Best Breakout Stocks to Buy According to Analysts
We recently published a list of 11 Best Breakout Stocks to Buy According to Analysts. In this article, we are going to take a look at where Zai Lab Limited (NASDAQ:ZLAB) stands against other best breakout stocks to buy according to analysts. Stock markets have been on edge in response to the US President’s aggressive […]
Gogo Inc. (GOGO): Among the Best Breakout Stocks to Buy According to Analysts
We recently published a list of 11 Best Breakout Stocks to Buy According to Analysts. In this article, we are going to take a look at where Gogo Inc. (NASDAQ:GOGO) stands against other best breakout stocks to buy according to analysts. Stock markets have been on edge in response to the US President’s aggressive trade […]
Enanta Pharmaceuticals, Inc. (ENTA): The Best Breakout Stock to Buy According to Analysts
We recently published a list of 11 Best Breakout Stocks to Buy According to Analysts. In this article, we are going to take a look at where Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) stands against other best breakout stocks to buy according to analysts. Stock markets have been on edge in response to the US President’s aggressive […]
Elanco Animal Health Sells Xdemvy Royalties To Blackstone in $295 Million Deal
Elanco Animal Health Incorporated (NYSE:ELAN) on Monday announced the sale of certain future tiered royalties and commercial milestones associated with Xdemvy (lotilaner ophthalmic solution) 0.25% for the human health application of lotilaner to Blackstone Life Sciences and Blackstone Credit & Insurance for $295 million in cash. The company will use the proceeds to accelerate debt reduction, positioning Elanco to achieve an expected net leverage ratio of 3.9x to 4.3x adjusted EBITDA by the end o
Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt Paydown
/PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the sale of certain future tiered royalties and commercial milestones associated...
Mentions: ELAN
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates
Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of 7.25% and 8.06%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: VNDA
Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements
Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000...
Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements
Will Declining Medical Customers Affect Cigna's Q1 Earnings?
CI's first-quarter results are likely to have benefited from growing pharmacy revenues and fees.
Wall Street Analysts See a 31.89% Upside in Tarsus Pharmaceuticals (TARS): Can the Stock Really Move This High?
The mean of analysts' price targets for Tarsus Pharmaceuticals (TARS) points to a 31.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
IRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30...
Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
Universal Health to Report Q1 Earnings: Can it Surprise Wall Street?
UHS' first-quarter earnings are likely to have benefited from growing admissions and patient days.
Molina Healthcare to Report Q1 Earnings: Key Estimates to Watch
MOH's first-quarter earnings are likely to have benefited from growing premiums, partially offset by higher expenses.
Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting
IRVINE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) will present four distinct data sets highlighting the...
Tarsus Announces Pricing of Upsized $125.0 Million Public Offering
Tarsus Announces Pricing of Upsized $125.0 Million Public Offering
IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the pricing of...
Tarsus Announces Proposed $100.0 Million Public Offering
Tarsus Announces Proposed $100.0 Million Public Offering
IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the...
Tarsus to Participate in Upcoming Investor Conference
IRVINE, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in a...